Journal article
Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study
M Bhurani, L Admojo, C Van Der Weyden, R Twigger, A Bazargan, H Quach, A Zimet, L Coyle, J Lindsay, D Radeski, E Hawkes, G Kennedy, I Irving, N Gutta, J Trotman, J Yeung, L Dunlop, M Hua, P Giri, S Yuen Show all
Leukemia and Lymphoma | TAYLOR & FRANCIS LTD | Published : 2021
Abstract
We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan–Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median O..
View full abstract